A detailed history of Russell Investments Group, Ltd. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 1,102 shares of AVIR stock, worth $3,647. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,102
Previous 504 118.65%
Holding current value
$3,647
Previous $1,000 200.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$3.17 - $4.02 $1,895 - $2,403
598 Added 118.65%
1,102 $3,000
Q2 2024

Aug 08, 2024

SELL
$3.31 - $4.04 $562 - $686
-170 Reduced 25.22%
504 $1,000
Q1 2024

May 08, 2024

SELL
$3.09 - $4.56 $13,089 - $19,316
-4,236 Reduced 86.27%
674 $2,000
Q4 2023

Feb 05, 2024

BUY
$2.8 - $3.35 $674 - $807
241 Added 5.16%
4,910 $14,000
Q3 2023

Nov 13, 2023

BUY
$3.0 - $3.79 $483 - $610
161 Added 3.57%
4,669 $14,000
Q1 2023

May 09, 2023

SELL
$3.0 - $4.97 $37,500 - $62,125
-12,500 Reduced 73.49%
4,508 $15,000
Q4 2022

Feb 08, 2023

BUY
$4.35 - $6.17 $54,374 - $77,125
12,500 Added 277.28%
17,008 $81,000
Q3 2022

Nov 04, 2022

BUY
$5.49 - $8.79 $4,968 - $7,954
905 Added 25.12%
4,508 $25,000
Q2 2022

Jul 29, 2022

SELL
$5.33 - $8.18 $31,654 - $48,581
-5,939 Reduced 62.24%
3,603 $26,000
Q1 2022

May 05, 2022

SELL
$5.5 - $9.19 $854,810 - $1.43 Million
-155,420 Reduced 94.22%
9,542 $67,000
Q4 2021

Jan 21, 2022

BUY
$7.67 - $44.59 $172,176 - $1 Million
22,448 Added 15.75%
164,962 $1.48 Million
Q3 2021

Nov 08, 2021

BUY
$21.33 - $35.06 $3 Million - $4.94 Million
140,818 Added 8302.95%
142,514 $4.93 Million
Q2 2021

Aug 04, 2021

BUY
$19.22 - $59.08 $32,597 - $100,199
1,696 New
1,696 $41,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $276M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.